Results 131 to 140 of about 37,220 (200)

Durable response to third-line combination therapy in a metastatic colorectal cancer patient with BRAF V600E mutation: A case report. [PDF]

Hum Vaccin Immunother
Zhang Q, Li L, Qian X.
europepmc   +1 more source

BRAF V600E mutation in thyroid carcinoma: a large-scale study in Han Chinese population. [PDF]

World J Surg Oncol
Cong R, Ouyang H, Zhou D, Li X, Xia F.
europepmc   +1 more source

BRAF V600E mutation and high expression of PD-L1 in Rosai-Dorfman disease: case report and review of the literature. [PDF]

J Hematop
Moen FM, Youssef MM, Shukla M, Nierodzik ML, Mayerhoefer ME, Park C.   +5 more
europepmc   +1 more source

A case report of neoadjuvant targeted therapy in stage IIIA non-small cell lung cancer with <i>BRAF V600E</i> mutation. [PDF]

Front Med (Lausanne)
Peng W, Qu S, Cai L, Yang R, Dong M, Li X, Ran F, Luo C.   +7 more
europepmc   +1 more source

Pancreatitis After Treatment With Encorafenib, Binimetinib, and Cetuximab for BRAF V600E Mutation-Positive Colorectal Cancer. [PDF]

Cureus
Kureyama Y, Hanaoka Y, Tomita D, Matoba S, Kuroyanagi H.   +4 more
europepmc   +1 more source

An Overview on Prevalence and Detection Approaches of BRAF V600E Mutation in Anaplastic Thyroid Carcinoma: A Systematic Review and Meta-Analysis. [PDF]

Iran J Public Health
Behnagh AK, Eghbali M, Abdolmaleki F, Ghadikolaei OA, Asl PR, Afsharpad M, Cheraghi S, Honardoost M.   +7 more
europepmc   +1 more source

Analysis of Immunohistochemical Expression of BRAF (V600E) Mutation in Serrated Colorectal Polyps: A Study from Tertiary Hospital in Oman. [PDF]

Asian Pac J Cancer Prev
Al Ghafri A, Sayed SG, Al Badi S, Al Rashdi A, Al Husaini S, Qureshi A, Shalaby A.   +6 more
europepmc   +1 more source

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.

Blood, 2023
Kreitman RJ, Moreau P, Ravandi F, Hutchings M, Gazzah A, Michallet AS, Wainberg ZA, Stein A, Dietrich S, de Jonge MJA, Willenbacher W, De Grève J, Arons E, Ilankumaran P, Burgess P, Gasal E, Subbiah V.   +16 more
europepmc   +1 more source

Clinicopathological Features and Prognosis of Unresectable Colorectal Cancer With the <i>BRAF V600E</i> Mutation. [PDF]

Cancer Diagn Progn
Ono Y, Numata K, Iguchi K, Uchiyama M, Asari M, Rino Y, Saito A, Shiozawa M.   +7 more
europepmc   +1 more source

Negative reactions of BRAF mutation-specific immunohistochemistry to non-V600E mutations of BRAF

Negative reactions of BRAF mutation-specific immunohistochemistry to non-V600E mutations of BRAF
BRAF mutations are rare driver mutations in non-small cell lung cancer (NSCLC), accounting for 1%–2% of the driver mutations, and the mutation spectrum has a wide range in contrast to other tumors. While V600E is a dominant mutation in melanoma, more than half of the mutations in NSCLCs are non-V600E.
openaire